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Case report
Late recovery with cyclosporine-A of an auto-immune 
sudden sensorineural hearing loss
Recupero tardivo della funzionalità uditiva con terapia con ciclosporina A  
in un caso di ipoacusia neurosensoriale improvvisa di origine immuno-mediata
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SummAry
Sensorineural hearing loss of immune-mediated origin may be present as a symptom in systemic autoimmune diseases or may occur as a 
primary disorder without other organ involvement (auto-immune inner ear disease). The diagnosis of auto-immune inner ear disease is still 
predicated on clinical features and to date specific diagnostic tests are not available. We report a case of right-sided sudden hearing loss in 
a female patient in which the clinical manifestations, in addition to AnA positivity and hypocomplementaemia allowed us to hypothesize 
an auto-immune inner ear disease. The immunosuppressive treatment with cyclosporine-A was capable of a recovery of the hearing that, 
however, occurred progressively with normalization of the hearing function after 1 year of treatment. cyclosporine-A could be proposed as 
a therapeutic option in case of auto-immune inner ear disease allowing the suspension of corticosteroids that, at high dose, expose patients 
to potentially serious adverse events.
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riASSunTo
L’ipoacusia neurosensoriale di origine immuno-mediata può rappresentare uno dei sintomi di malattie autoimmuni sistemiche o può 
manifestarsi come disturbo primario, senza il coinvolgimento di altri organi (malattia auto-immune dell’orecchio interno). La diagnosi 
di malattia auto-immune dell’orecchio interno è ancora basata sulle caratteristiche cliniche e, al momento, non sono disponibili test dia-
gnostici accurati. Segnaliamo il caso di una paziente affetta da perdita improvvisa dell’udito in orecchio destro in cui, le manifestazioni 
cliniche, il riscontro di ANA-positività e di ipocomplementemia ha permesso di ipotizzare una malattia auto-immune dell’orecchio interno. 
Il trattamento immunosoppressivo con ciclosporina A è stato in grado di indurre un recupero dell’udito che, tuttavia, si è verificato in 
maniera progressiva nel tempo con la normalizzazione della funzione uditiva dopo 1 anno di trattamento. Un trattamento a bassi dosaggi 
e a lungo termine con ciclosporina A potrebbe essere proposto come opzione terapeutica in caso di malattia auto-immune dell’orecchio 
interno permettendo la sospensione della terapia steroidea potenzialmente gravata da effetti collaterali anche gravi.
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Introduction
Sudden sensorineural hearing loss (SShl) is frequent: the 
overall incidence ranges from 5 to 20 per 100,000 persons 
per year 1. SShl is a syndrome of unknown aetiology of-
ten accompanied by vertigo and tinnitus. Sensorineural 
hearing loss of immune-mediated origin may be present 
as a symptom in systemic autoimmune diseases (Cogan’s 
syndrome, Behçet’s disease, Wegener’s granulomatosis, 
mixed  cryoglobulinaemia,  systemic  sclerosis,  systemic 
lupus erythematosus, giant cell arteritis, panarteritis no-
dosa, relapsing polychondritis) or may occur as a primary 
disorder without other organ involvement (auto-immune 
inner  ear  disease)  (Aied).  Although  Aied  is  usually 
bilateral  and  rapidly  progressive,  in  some  cases  it  can 
present suddenly and unilaterally 2. The diagnosis of Aied 
is still predicated on clinical features, while indirectly on 
positive therapeutic response to corticosteroids 3. To date 
specific diagnostic tests are not available 4. in Aied, an 
immune dysregulation has been hypothesized as pathoge-
netic mechanism due to the presence, in some patients, of 
AnA 5, hypocomplementaemia and autoantibodies against 
the inner ear neuroepithelium and the endothelial cells 2 in 
presence of normal inflammation indices.
Case report
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ter discharge the patient presented partial recovery of the 
right hearing that continued over time, with normalization 
of the hearing function after 1 year of treatment (Fig. 1). 
during the first year, bimonthly clinical and laboratory 
follow-up was introduced, while thereafter four-monthly 
follow-up was carried out. All these evaluations, by moni-
toring the response to the new treatment protocol and de-
tecting any side-effects that might stem from the inclusion 
of CsA, revealed normal renal and hepatic function and 
absence of gastrointestinal side-effects.
The clinical improvement associated with the absence of 
inflammation, normalization of complement level and ab-
sence of AnA allowed gradual steroid tapering and lim-
ited reduction of the CsA daily dosage. From may 2008 
to november 2008, the patient was on a maintenance pro-
tocol consisting of CsA (100 mg/day) and salicylic acid 
(100 mg/day). At follow-up 24 months after hospitalisa-
tion, hearing was normal on the right side (pTA 20.8 dB 
hl) with normal speech discrimination (100% at 40 dB) 
(Fig. 1). Acoustic reflexes were present upon ipsi-lateral 
and contra-lateral stimulation with normal thresholds and 
otoacustic emissions reappeared on the right side. Bither-
mal caloric stimulation and vemps showed normal ves-
tibular function. Thereafter, with gradual tapering, CsA 
was discontinued on may 2009 and at the last follow-up, 
in november 2009, the patient presented the same pTA 
and speech discrimination as in the evaluation made 24 
months after hospitalization (Fig. 1).
Discussion
no guidelines have been established for the treatment of 
Aied. high doses of steroids are usually the only treatment 
(generally prednisone 1 mg/kg/day) able to partially restore 
ear function. immunosuppressive agents (methotrexate, cy-
clophosphamide or azathioprine) are of poor efficacy 3. in 
our case, after careful assessment of the risks and benefits 
the otolaryngology department of the university of Bari 
with right-sided hearing loss that had appeared suddenly, 
72 hours before admission. The patient’s medical history 
was negative for diabetes, hypertension, dyslipidaemia, 
thyroid  dysfunction  and  intake  of  contraceptive  drugs. 
on hospital admittance, the patient reported right-sided 
hearing loss, fullness and tinnitus, no vertigo or dizzi-
ness were reported. Both tympanic membranes were nor-
mal, there were no signs of vestibular involvement, and 
the neuro-otologic examination was completely normal. 
hearing  test  showed  a  flat,  right-sided  profound  sen-
sorineural hearing loss. pure tone average (pTA) for the 
frequencies from 0.125 to 8 khz was 94.3 dB on the right 
side and 14.3 dB hl on the left side. maximum speech 
discrimination score was 10% at 100 dB hl on the right 
and 100% at 30 dB hl on the left side. Acoustic reflexes 
were evoked on the left side; on the right side, ipsilateral 
reflexes were absent and contra-lateral reflexes presented 
an increased threshold at 0.5 and 1 khz. reflex decay 
test was normal bilaterally. Auditory brainstem responses 
were absent on the right side and normal on the left side. 
Transient  evoked  otoacoustic  emissions  and  distortion 
product otoacoustic emission input/output function at 2, 4 
and 6 khz were absent on the right side and normal on the 
left. The bithermal caloric test showed a right vestibular 
hyporeflexia of 34% according to Jonkee’s formula, while 
vestibular  evoked  myogenic  potentials  (vemps)  were 
normal bilaterally.
laboratory tests showed a slightly reduced C3 fraction 
(0.84 g/l, ref. values 0.90-1.8 g/l) and AnA (1:160, ho-
mogeneous  pattern). Total  cholesterol,  eSr,  Crp,  α2-
globulins,  blood  fibrinogen,  circulating  immune  com-
plexes,  anti-dsdnA,  p-AnCA,  c-AnCA,  enA,  ACA, 
anti-β2 glycoprotein were normal. The patient was initial-
ly treated with prednisone 55 mg/day, xanthinol nicoti-
nate 2 g/day, ascorbic acid 1 g/day, vitamin e 200 mg/day, 
pentoxifillin (600 mg/day), enoxaparin (4000 ui/day) and 
carbogen (95% o2 5% Co2).
Ten days after this treatment, a slight recovery in the hear-
ing threshold (pTA 83.5 dB hl) and of the speech dis-
crimination (50% at 100 dB) was scored. on the basis of 
the immunologic work-up at the Allergology and Clinical 
immunology Section of the university of Bari, the patient 
started treatment with Cyclosporine-A (CsA) (Sandim-
mun neoral® novartis Farma SpA, varese, italy) 125 mg/
day in association with steroid, haemorheologic treatment 
already established. The choice of this immunosuppres-
sive therapy, at low dosage, was necessary due both to the 
severity of symptoms and the presence of immune dys-
regulation confirmed by AnA positivity and hypocomple-
mentaemia.
Twelve  days  after  hospitalization  the  patient  was  dis-
charged with a pTA of 80.7 dB hl and a speech dis-
crimination of 50% at 100 dB. regression of fullness and 
improvement of tinnitus were observed. Two weeks af-
Fig. 1. Hearing test and speech discrimination in right (●) and left (■) ear 
at: a) hospital admission; b) hospital discharge; c) 15 days after discharge; 
d) 20 months after discharge.late recovery with cyclosporine-A of an auto-immune sudden hearing loss
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of  immunosuppressive  therapy,  prompt  treatment  with 
steroids and CsA, in addition to haemoreological agents, 
led to recovery of hearing that, however, occurred pro-
gressively. The clinical improvement started 15 days af-
ter hospital discharge and progressed over one year. The 
excellent response to CsA, in the form of recovery of the 
right hearing, together with normalisation of C3 and dis-
appearance of AnA, was then, maintained over the years. 
CsA, by inhibiting T-lymphocyte synthesis of various cy-
tokines (in particular il-2, il-4) and inducing a reduc-
tion in the Cd40 ligand expression, is responsible for the 
inhibition of the T and B cell interaction. This mechanism 
induces a reduction in antibody production 6. in our case, 
the CsA, at a low dosage, was found to be an efficient 
form of treatment that led to the reduction and subsequent 
suspension of the steroid dosage. no adverse drug reac-
tions were recorded during the treatment. in addition, the 
beneficial effect of the CsA treatment was maintained for 
five months after suspension.
Conclusions
in the light of these findings, CsA could be proposed, at 
low dosage, as a therapeutic option in case of SShl show-
ing laboratory signs of immune dysregulation, although 
it is rare to find clear signs of immunological changes. 
in fact, the use of CsA resulted effective also in the case 
of idiopathic sensorineural hearing loss 7. This molecule 
showed a good safety and efficacy profile allowing sus-
pension of corticosteroids that, at a high dose, expose pa-
tients to potentially severe adverse events. CsA may be 
assigned as long-term treatment, considering the chance 
of a late recovery by scrupulous monitoring of the renal 
and hepatic function.
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